Biopartners to Appeal the CHMP's Negative Opinion on Its Novel Interferon beta-1a.BAAR, Switzerland -- Biopartners GmbH has announced that it will request a re-assessment from the EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. in support of its novel interferon beta-1a, Biferonex([R]), after receiving a negative opinion from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP CHMP Committee for Medicinal Products for Human Use CHMP Cultural Heritage Management Plan CHMP Centrale Humanitaire Médico-Pharmaceutique CHMP Certified Hazardous Materials Practitioner (Institute of Hazardous Materials Managers) ). According to EMEA procedures Biopartners will continue their work to accomplish the registration of Biferonex. "We are convinced about the strength of our data based on the results of a Phase III trial. This shows that Biferonex demonstrated safety and efficacy profiles comparable to established interferon beta-1a products already on the market", said Biopartners' CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Jean-No[R]l Treilles. "We will therefore be working closely with the EMEA to support the newly-appointed rapporteur rap·por·teur n. One who is designated to give a report, as at a meeting. [Middle English raportour, judge, from Old French raporteur, from raporter, to bring back and co-rapporteur with any additional data that they need during the re-examination of the dossier. We believe that this is a very unique case as Biferonex is a novel formulation of an Interferon beta-1a that has already been approved in 1996 and 1997 in the US and EU". Commenting on the decision, Professor O. R. Hommes, Chairman of the European Charcot Foundation which coordinates MS research in Europe said "I look forward to the re-evaluation with interest. Having seen the results of the Phase III trial at key points throughout its development I would welcome Biopartners' interferon beta-1a as a new alternative therapy in the treatment of multiple sclerosis". The re-examination will last approximately 3-4 months. About Biferonex: Biferonex is an innovative pH neutral and human serum albumin (HSA HSA Health Savings Account (US) HSA Human Serum Albumin HSA Human Services Agency (Nevada) HSA Health Services Agency HSA Health and Safety Authority (Ireland) ) free formulation at physiological osmolarity osmolarity /os·mo·lar·i·ty/ (oz?mo-lar´i-te) the concentration of a solution in terms of osmoles of solutes per liter of solution. os·mo·lar·i·ty n. providing an alternative interferon beta treatment solution for patients suffering from relapsing remitting multiple sclerosis (RRMS RRMS Relapsing/Remitting Multiple Sclerosis RRMS Rosemont Ridge Middle School (West Linn, Oregon) RRMS Rocky Run Middle School (Virginia) RRMS Recoverable Resource Management Services ). About the MS market: The World Health Organization estimates that multiple sclerosis affects 2.5 million people worldwide and is one of the most common neurological disorders and causes of disability of young adults, especially in Europe and North America. According to the Datamonitor, the global MS market continues to grow at a steady rate and was estimated to be worth over $5.3 billion in 2007. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion